Medtronic: The Defensive Play Hiding in Plain Sight

There’s a category of stock that tends to get ignored during bull markets and quietly re-rated when things get uncertain. Medtronic ($MDT) fits that description almost perfectly right now. It’s not exciting. It’s not a momentum trade. But when rate anxiety picks back up and macro visibility thins out, hospitals don’t delay pacemaker implants, and chronic disease patients don’t pause insulin pump therapy. That’s the whole thesis – and the numbers are starting to back it up in a serious way.

The FY2026 Numbers – Highest Growth in a Decade

Medtronic just reported full fiscal year 2026 results on June 3, 2026. The headline: $36.364 billion in total revenue, up 8.4% as reported and 5.8% on an organic basis – the company’s highest annual revenue growth in 10 years. Q4 alone came in at $9.807 billion, growing 9.9% as reported and 6.6% organically, beating implied guidance by 90 basis points.

On the earnings side, FY26 GAAP diluted EPS was $3.73, up 3.3% year-over-year. Non-GAAP diluted EPS reached $5.53, up 0.7%. Free cash flow for the full year came in at $5.426 billion, up 4.6%, representing 76% conversion from non-GAAP net earnings. These are not flashy numbers, but they are consistent – and in the current environment, consistency is underpriced.

The Cardiovascular segment is where the real action is. Q4 Cardiovascular revenue grew 10.1% organically. Cardiac Ablation Solutions – powered by Medtronic’s pulsed field ablation (PFA) portfolio – posted 78% global revenue growth in Q4, including 124% U.S. growth, gaining an additional 8 points of U.S. share in a single quarter. Mid-teens growth in Micra transcatheter pacing systems continued through the quarter, with the OmniaSecure defibrillation lead also gaining traction following its U.S. launch. For context, Micra VR and VR2 already hold approximately 47% revenue share in the global leadless pacemaker market.

Why the Defensive Angle Matters Right Now

Here’s what the pure-growth crowd tends to skip over: medical devices sit at the intersection of non-discretionary demand and institutional inertia. A hospital system does not cut cardiovascular procedures when inflation runs hot. A cardiologist does not delay pacemaker implants because the Fed held rates. The procedure volume is structurally driven by an aging global population and the rising prevalence of chronic conditions – not by consumer sentiment or credit availability.

Medtronic operates across cardiovascular devices, neuroscience, surgical instrumentation, and diabetes monitoring. That breadth is actually a feature in a risk-off environment – no single reimbursement change or competitive shift takes out the whole business. The Medical Surgical segment posted 5.1% growth in Q4, with Acute Care and Monitoring up low-double-digits. These aren’t high-multiple growth categories, but they generate durable cash flows that fund the dividend and the innovation pipeline simultaneously.

One thing worth flagging – Medtronic announced its intent to separate the Diabetes business into a standalone public company via a series of capital markets transactions, with an IPO as the preferred path. That separation is expected to be accretive to Medtronic’s gross margin, operating margin, and EPS over time. It also sharpens the remaining business around its highest-conviction cardiovascular and neuroscience franchises. The market hasn’t fully priced in what a cleaner, more focused Medtronic looks like on a margin basis.

Valuation – Discount That’s Hard to Ignore

MDT is currently trading around the high-$70s. The trailing P/E sits at approximately 20.6x, well below its 3-year average of 27.2x and its 5-year average of 28.8x. The forward P/E is approximately 12.2x based on consensus estimates. For a company generating $36+ billion in revenue with 5–6% organic growth and raising FY2027 organic growth guidance to 6.75% to 7.25%, that multiple looks dislocated from fundamentals.

The dividend adds another layer. Medtronic raised its dividend for the 49th consecutive year – quarterly dividend is now $0.72 per share, implying $2.88 annualized. That produces a dividend yield of approximately 3.3% at current prices. The payout ratio is around 76%. Not a concern for a business generating $5.4 billion in annual free cash flow. The consensus analyst price target across 30 analysts is approximately $105.76, implying more than 40% upside from current levels. Zero sell ratings in the analyst community.

For context on the peer group: the broader medical devices and instruments industry trades at an average P/E near 34x. MDT sits at roughly 21x. That’s a meaningful discount for a company with the scale, global distribution, and franchise depth that Medtronic carries.

Technical Structure

The stock has been range-bound through the mid-$70s to low-$80s over recent months after a prolonged multi-year compression from the $110–120 range. Current price action reflects sector multiple compression more than fundamental deterioration. Key levels to watch: the $80 level has acted as near-term resistance, while the $72–73 zone has provided support on recent pullbacks. The 200-day moving average remains a ceiling until a sustained earnings or guidance catalyst drives a reclaim.

Volume on recent down days has been relatively light – suggesting the selling pressure is positional rather than fundamental. The post-Q4 earnings reaction was muted despite a solid beat, which is either a near-term negative or a setup for delayed recognition. That kind of non-reaction after a beat is worth paying attention to.

Scenario Framework

• Bull Case: FY2027 organic revenue growth hits the high end of 7.25% guidance. Cardiovascular PFA adoption accelerates further – Cardiac Ablation Solutions has now posted back-to-back quarters of 71%+ and 78% growth globally. The Diabetes separation is executed cleanly and margin expansion materializes. MDT reclaims the $90–100 range as the multiple compresses less relative to peers. Analyst target convergence toward $105–$121 becomes a tailwind.
• Base Case: Medtronic continues mid-single-digit organic growth, the Cardiovascular segment sustains leadership in pacing and ablation, and the stock gradually drifts toward the $85–$95 range as valuation re-rates modestly. Dividend income provides a floor on total return math at current levels. FY2027 guidance is met without major earnings variance.
• Bear Case: Macro-driven hospital capital spending freezes delay elective device procedures. Foreign currency headwinds – which already impacted FY26 non-GAAP EPS by $0.15 – intensify. Tariff pressures on manufacturing erode margins further; the company noted a 50 basis point operating margin impact from tariffs in FY26. The Diabetes IPO process encounters friction. Stock tests the $68–72 support zone.

Active Trader Positioning Considerations

The risk/reward math here is not complicated. You have a $36+ billion revenue business, the highest organic growth in a decade, 49 consecutive years of dividend increases, zero sell ratings, and a forward multiple near 12x. The friction is the macro backdrop – sector multiples are compressed across medtech broadly, and the post-earnings reaction suggests positioning remains cautious.

For traders watching key levels: $80 on the upside is the near-term level to monitor for a momentum shift. Sustained trade above that level with improving volume would change the character of the move. On the downside, the $72–73 zone is where risk management decisions become important. Volatility expectations here are moderate – this is not a high-beta event-driven name, but options activity around the Diabetes separation timeline could introduce episodic vol.

Position sizing should account for the macro sensitivity of the broader sector. Even non-cyclical medical devices are not immune to sentiment-driven selling during broad risk-off episodes. What they tend to do is recover faster, with dividend support acting as a cushion. That dynamic is worth factoring into any duration decision.

The broader point is this: Medtronic just delivered its best annual growth in a decade, guided for acceleration into FY2027, and trades at a meaningful discount to both its own historical averages and its peer group. The market is looking elsewhere right now. That tends to be when the best risk/reward exists in defensive compounders – not after they’ve already moved. Preparation, not reaction, is what separates disciplined positioning from chasing.

For informational and educational purposes only. Not investment advice. Trading involves risk, including loss of principal.